JP2010520921A - 肝疾患および肝炎の治療に用いるための、ｉｌ−８遮断薬および／またはｔｒａｉｌ遮断薬を含む組成物 - Google Patents

肝疾患および肝炎の治療に用いるための、ｉｌ−８遮断薬および／またはｔｒａｉｌ遮断薬を含む組成物 Download PDF

Info

Publication number
JP2010520921A
JP2010520921A JP2009553199A JP2009553199A JP2010520921A JP 2010520921 A JP2010520921 A JP 2010520921A JP 2009553199 A JP2009553199 A JP 2009553199A JP 2009553199 A JP2009553199 A JP 2009553199A JP 2010520921 A JP2010520921 A JP 2010520921A
Authority
JP
Japan
Prior art keywords
trail
blocker
ifn
agent
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009553199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010520921A5 (https=
Inventor
ケー． マイニ，マーラ
Original Assignee
ユーシーエル ビジネス パブリック リミテッド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシーエル ビジネス パブリック リミテッド カンパニー filed Critical ユーシーエル ビジネス パブリック リミテッド カンパニー
Publication of JP2010520921A publication Critical patent/JP2010520921A/ja
Publication of JP2010520921A5 publication Critical patent/JP2010520921A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2009553199A 2007-03-09 2008-03-07 肝疾患および肝炎の治療に用いるための、ｉｌ−８遮断薬および／またはｔｒａｉｌ遮断薬を含む組成物 Pending JP2010520921A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0704651.9A GB0704651D0 (en) 2007-03-09 2007-03-09 Composition
PCT/GB2008/000811 WO2008110771A2 (en) 2007-03-09 2008-03-07 Composition comprising an il-8 blocking agent and/or a trail blocking agent for use in the treatment of liver disease and hepatic flares

Publications (2)

Publication Number Publication Date
JP2010520921A true JP2010520921A (ja) 2010-06-17
JP2010520921A5 JP2010520921A5 (https=) 2011-04-21

Family

ID=37988738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009553199A Pending JP2010520921A (ja) 2007-03-09 2008-03-07 肝疾患および肝炎の治療に用いるための、ｉｌ−８遮断薬および／またはｔｒａｉｌ遮断薬を含む組成物

Country Status (5)

Country Link
US (1) US20100040632A1 (https=)
EP (1) EP2124995A2 (https=)
JP (1) JP2010520921A (https=)
GB (1) GB0704651D0 (https=)
WO (1) WO2008110771A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512412A (ja) * 2012-03-28 2015-04-27 アムジェン インコーポレイテッド Ｄｒ５受容体アゴニストの組み合わせ

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846576B2 (en) 2011-05-27 2014-09-30 Xenotech Llc In vitro test system to evaluate xenobiotics as immune-modulators of drug transport and metabolism in human hepatocytes
CN111450232B (zh) * 2019-01-21 2023-08-01 中国科学院深圳先进技术研究院 一种融合蛋白在制备治疗丙型肝炎药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501470A (ja) * 1999-06-16 2003-01-14 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
JP2006523088A (ja) * 2002-12-16 2006-10-12 メダレックス， インク． インターロイキン８（ｉｌ−８）に対するヒトモノクローナル抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038854A1 (en) * 2001-07-16 2004-02-26 Dillon Susan B. Use of il-8 receptor antagonists in the treatment of virus infections
US20060228352A1 (en) * 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501470A (ja) * 1999-06-16 2003-01-14 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
JP2006523088A (ja) * 2002-12-16 2006-10-12 メダレックス， インク． インターロイキン８（ｉｌ−８）に対するヒトモノクローナル抗体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5010004550; Ｃ．ＤＵＮＮ: 'ＩＭＭＵＮＯＭＯＤＵＬＡＴＯＲＹ　ＥＦＦＥＣＴＳ　ＯＦ　ＴＨＥ　ＬＡＲＧＥ　ＦＬＵＣＴＵＡＴＩＯＮＳ　ＩＮ　ＩＦＮ-ＡＬＰＨＡ　以下備考' ＪＯＵＲＮＡＬ　ＯＦ　ＨＥＰＡＴＯＬＯＧＹ Ｖ４２, 20050401, Ｐ１４６, ＭＵＮＫＳＧＡＡＲＤ　ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＰＵＢＬＩＳＨＥＲＳ *
JPN6012062362; ＬＩＵ，Ｙ．Ｇ．　ｅｔ　ａｌ: 'Ｂｌｏｃｋａｄｅ　ｏｆ　ＴＲＡＩＬ　ｐａｔｈｗａｙ　ａｍｅｌｉｏｒａｔｅｓ　ＨＢＶ-ｉｎｄｕｃｅｄ　ｈｅｐａｔｏｃｙｔｅ　ａｐｏｐｔｏｓｉｓ　ｉｎ　ａｎ　ａｃｕｔｅ　ｈｅｐａｔｉｔｉｓ　ｍｏｄｅｌ' Ｂｉｏｃｈｅｍ　Ｂｉｏｐｈｙｓ　Ｒｅｓ　Ｃｏｍｍｕｎ Ｖｏｌ．３５２，　Ｎｏ．２, 2007, ｐ．３２９-３４ *
JPN6012062364; ＬＩＡＮＧ，Ｘ．　ｅｔ　ａｌ: 'Ｈｅｐａｔｉｔｉｓ　Ｂ　ｖｉｒｕｓ　ｓｅｎｓｉｔｉｚｅｓ　ｈｅｐａｔｏｃｙｔｅｓ　ｔｏ　ＴＲＡＩＬ-ｉｎｄｕｃｅｄ　ａｐｏｐｔｏｓｉｓ　ｔｈｒｏｕｇｈ　Ｂａｘ' Ｊ　Ｉｍｍｕｎｏｌ Ｖｏｌ．１７８，　Ｎｏ．１, 2007, ｐ．５０３-１０ *
JPN6012062366; ＨＥＡＴＨＣＯＴＥ，Ｊ．: 'Ｔｒｅａｔｍｅｎｔ　ｏｆ　ＨＢｅ　ａｎｔｉｇｅｎ-ｐｏｓｉｔｉｖｅ　ｃｈｒｏｎｉｃ　ｈｅｐａｔｉｔｉｓ　Ｂ' Ｓｅｍｉｎ　Ｌｉｖｅｒ　Ｄｉｓ Ｖｏｌ．２３，　Ｎｏ．１, 2003, ｐ．６９-８０ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512412A (ja) * 2012-03-28 2015-04-27 アムジェン インコーポレイテッド Ｄｒ５受容体アゴニストの組み合わせ

Also Published As

Publication number Publication date
WO2008110771A2 (en) 2008-09-18
EP2124995A2 (en) 2009-12-02
GB0704651D0 (en) 2007-04-18
US20100040632A1 (en) 2010-02-18
WO2008110771A3 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
Dunn et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage
Ogata et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis–induced hepatocarcinogenesis
Ikeda et al. Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice
Zhou et al. High mobility group box chromosomal protein 1 in acute-on-chronic liver failure patients and mice with ConA-induced acute liver injury
Jaruga et al. Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes
Rossi et al. Interleukin-6 as a therapeutic target
Ravichandran et al. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice
Bartneck et al. Histidine‐rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease
Campbell et al. Proinflammatory cytokine production in liver regeneration is Myd88-dependent, but independent of Cd14, Tlr2, and Tlr4
Marra Chemokines in liver inflammation and fibrosis
Crespo et al. Gene expression of tumor necrosis factor [alpha] and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients
Chu et al. C‐C motif chemokine receptor 9 positive macrophages activate hepatic stellate cells and promote liver fibrosis in mice
Amiot et al. Expression of HLA-G by mast cells is associated with hepatitis C virus-induced liver fibrosis
Yin et al. SDF-1α involved in mobilization and recruitment of endothelial progenitor cells after arterial injury in mice
Wang et al. CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice
Huang et al. Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy
Sansonno et al. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis
Miyagaki et al. CCL11–CCR3 interactions promote survival of anaplastic large cell lymphoma cells via ERK1/2 activation
JP2008524242A (ja) 自己免疫障害を治療する方法
Bideak et al. The atypical chemokine receptor 2 limits renal inflammation and fibrosis in murine progressive immune complex glomerulonephritis
Janovec et al. Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes
da Rosa Franchi Santos et al. Influence of treatments on cell adhesion molecules in patients with systemic lupus erythematosus and rheumatoid arthritis: a review
Müller et al. Exclusive expression of transmembrane TNF aggravates acute glomerulonephritis despite reduced leukocyte infiltration and inflammation
JP2010520921A (ja) 肝疾患および肝炎の治療に用いるための、ｉｌ−８遮断薬および／またはｔｒａｉｌ遮断薬を含む組成物
Kireva et al. Transcription factor Fra‐1 induces cholangitis and liver fibrosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130423